CD19 and chronic myelogenous leukemia, BCR-ABL1 positive: In Philadelphia chromosome-positive CML, blinatumomab a bispecific anti-CD3/CD19 monoclonal antibody demonstrated efficacy when combined with TKIs such as dasatinib64.